Introduction {#S0001}
============

Due to its invasive and metastatic characteristics, pancreatic ductal adenocarcinoma (PDAC), also known as pancreatic cancer, is characterized by one of the most malignant tumors.[@CIT0001] The difficulty in the early diagnosis makes matters worse. Even though there are many kinds of treatments for pancreatic cancer such as operative treatment, chemotherapy, and so on, patients who had pancreatic cancer still have a poor prognosis. Pancreatic cancer accounts for the seventh cause of cancer-related mortality in China.[@CIT0002] As a result, there is a need to identify more effective prognostic indicators. Without such enormous progress in the genomics and proteomics in the pancreatic cancers, numerous searchers change their targets to micro-environment of tumors, which are involved with heterogeneous inflammatory cells. These inflammatory cells contribute to the initiation, growth and distant metastasis.[@CIT0003] Among them, tumor-associated macrophages are of great significance, originating from circulating monocytes. It is shown that tumor-associated macrophages can be divided into two classes of type 1 macrophages (M1) and type 2 macrophages (M2).[@CIT0004] M1 macrophages, also known as classically activated macrophages, are activated by Th1 cytokines to promote the response of inflammatory and the activities of anti-tumor. On the contrary, M2 macrophages (labeled by CD163, CD204, CD206, and so on), also known as alternatively activated macrophages, are activated by Th2 cytokines, which play a critical role in the pro-tumor activities such as anti-inflammatory, tissue remodeling, tumor proliferation, invasion, and metastasis.

Tumor-associated macrophages are now recognized as prognostic indicators in many solid tumors. A few studies verified that the high expression of TAMs associated with poor prognosis in gastric cancer,[@CIT0005] ovarian cancer,[@CIT0006] and non-small-cell lung cancer.[@CIT0007] But an increased density of TAMs in the invasive front of colon cancer associated with favorable prognosis.[@CIT0008] However, the impact of tumor-associated macrophages on patient prognosis in pancreatic cancer still exists controversy among previous studies.[@CIT0009]--[@CIT0011] What's more, the biomarkers of tumor-associated macrophages in each study are not the same and the numbers of samples from the patients in each study variated. In order to solve these problems, we performed a meta-analysis to evaluate the potential association between TAMs density and the prognosis of pancreatic cancer.

Materials and methods {#S0002}
=====================

We conducted this meta-analysis based on the PRISMA guidelines. Ethical approval and informed consent are not needed because of the reason that the studies included in this meta-analysis are previously published.

Search strategy {#S0002-S2001}
---------------

We retrieved related articles about the prognostic value of TAMs in patients with pancreatic cancer, which was published before November 2018, from PubMed databases, Embase and Web of Science. The following search terms were variously combined: "pancreatic cancer", "pancreatic carcinoma", "pancreatic duct adenocarcinoma", "pancreatic ductal adenocarcinoma", "macrophage", "tumor-associated-macrophages", "tumor-infiltrating-macrophages", "tumor infiltrating macrophages", and "TAMs". The full electronic strategy of databases is listed in Supplementary text 1. To identify potentially eligible articles, we checked titles and abstracts, and then reviewed full texts. What's more, we also manually checked the reference entries of the relevant literature to avoid the omission.

Inclusion criteria and exclusion criteria {#S0002-S2002}
-----------------------------------------

The articles were reviewed by two authors. And disagreements were reached consensus by discussion. The study was included in this meta-analysis if meeting the following inclusion criteria: (1) being published in the English language, (2) researching pancreatic cancer patients, (3) investigating the information of TAMs expression, and (4) focusing on the association between TAMs and survival rates of patients with pancreatic cancer. Articles were excluded if meeting any of the following exclusion criteria: (1) not analyzing the prognosis value of pancreatic cancer; (2) not providing sufficient data to extract HRs and 95% confidence intervals (95% CIs); (3) reporting duplicate or overlapping data; (4) being specific literature such as animal studies, case reports, comments, reviews, and meeting abstracts; and (5) not full-text.

Outcomes of interest {#S0002-S2003}
--------------------

The foremost outcomes of interest in our meta-analysis were overall survival (OS), disease-free survival (DFS), and relapse-free survival (RFS). Other outcomes of interest were lymph node (LN) metastasis, tumor stage, histological grade, sex, and tumor location.

Evaluation of the publication's quality {#S0002-S2004}
---------------------------------------

We evaluated the quality of the original publications of three components: patient selection, study comparability and outcome assessment in the Newcastle--Ottawa scale (NOS) system.[@CIT0012] If a study obtained a score over 6, it can be regarded as a study of high equality. Two authors independently performed evaluation of the publications quality and the disagreements were reached consensus by robust discussion.

Data extraction {#S0002-S2005}
---------------

The datum was extracted by two authors independently from included studies. The following data were extracted from each study: author, publication year, country, median age, the proportion of men and women, tissue distribution, cut-off value, disease stage, duration of follow-up, examination methods; biomarkers, the proportion of positive outcomes and negative outcomes, estimate HRs, low limit of 95% confidence interval(LCI) and upper limit of 95% confidence interval (UCI) concerning the prognostic significance of TAMs, survival analysis, dilution and NOS score. HRs and their 95% CIs were given directly in most of the original studies. Because of the fact that a few included studies presented survival curves rather than the HRs, hence we made use of the Engauge Digitizer 4.1 software to calculate HRs.[@CIT0013]

HR and 95% CI statistical analysis {#S0002-S2006}
----------------------------------

Using HRs with 95% CIs, we investigate the association between the TAMs density and prognosis of patients with pancreatic cancer according to Tierney's method.[@CIT0014] Using Odds ratios (ORs) with CIs, we evaluated the correlation between the TAMs density and clinicopathological characteristics. The pooled results were presented with forest plots. If a pooled HR or OR is \>1, it suggested there was a worse prognosis in the high TAMs density group. And if the 95% CI did not include 1, it was generally thought to indicate a statistically significant result. If a pooled HR or OR is \<1, it suggested there was a better prognosis in the high TAMs density group.

Heterogeneity among included studies was assessed by the Cochran's Q statistic and I^2^ tests. According to Higgins and Thompson (2003), the heterogeneity was defined as either I^2^\>50% or *P*-value \<0.10, in which case a random effect model would be used. If heterogeneity was not significant, we would choose a fixed effect model. We also conducted a subgroup analysis to seek the source of heterogeneity existing across studies.[@CIT0015] Meanwhile, by omitting a study at a time, a sensitivity analysis was performed to assess the stability. In addition, we performed Begg's test and Egger's test[@CIT0016] to confirm whether publication bias existed among the included publications. All the statistical analysis was based on STATA version 11. These processes were performed by two authors independently.

Results {#S0003}
=======

Search results and characteristics of the study {#S0003-S2001}
-----------------------------------------------

According to the inclusion criteria and exclusion criteria detailed in methods, 13 studies with macrophages detected by immunohistochemistry (IHC) or polymerase chain reaction (PCR) in tumor samples were included for meta-analysis. The flow chart of the search strategy is shown in [Figure 1](#F0001){ref-type="fig"}.Figure 1Flow diagram of study selection.

All the included studies published in English. The total sample size for all records was 1699, and the size ranged from 28 to 284.[@CIT0009]--[@CIT0011],[@CIT0017]--[@CIT0026] Among them, 6 cases enrolled less than 100 patients[@CIT0010],[@CIT0017]--[@CIT0020],[@CIT0026] and 7 studies[@CIT0009],[@CIT0011],[@CIT0021]--[@CIT0025] included more than 100 patients. The NOS scores of these studies ranged from 6 to 8. Thus, the quality of all included studies was good. Among these cases, the tissue distributions variated. First, seven cases detected TAMs in the tumor cell and stroma, and four cases focused on TAMs locating in tumor cell. Excepted that, two cases accessed TAMs locating in tumor cell. These studies enrolled patients from East Asia, Europe, and North America, including 5 from China, 5 from Japan, 2 from the USA, and 1 from Germany. When talking about prognostic endpoints in the included studies, OS, DFS, and RFS were used jointly or separately. Details of the characteristics of studies are shown in [Table 1](#T0001){ref-type="table"}.Table 1Basic information of included studiesAuthorPublished yearCountryPatient numberAge, median (range)Male/femaleStageThe follow-up, median (range)Examination methodsTissue distributionHiroshi Kurahara[@CIT0010]2011Japan7667.0 (42-81)52/24I- IVnot reportedimmunohistochemistrytumor cell and stromatumor cell and stromaKiyoshi Yoshikawa[@CIT0022]2012Japan10764.0 (37-82)64/44II- IVnot reportedimmunohistochemistrytumor stromatumor stromaY Ino[@CIT0009]2013Japan212not reported130/82I- IV18.8 (2.6--201) general ； 54.5 (2.6--201) livingimmunohistochemistrytumor cell and stromatumor cell and stromatumor cell and stromaYa-Chin Hou[@CIT0017]2014China96not reported63/33I- IV3.7years (range, 1.9-12.5 years)immunohistochemistrytumor stromatumor cell and stromaMotokazu Sugimoto[@CIT0024]2014Japan17065 (34-84)107/63II-IVnot reportedimmunohistochemistrytumour stromatumour stromaS.J. Chen[@CIT0019]2015China7058 (28-83)44/26I- IV\>2 Yearsimmunohistochemistrytumor celltumor stromaKazuki Takakura[@CIT0018]2015Japan2866.5 (44--77)16/12I-IIInot reportedimmunohistochemistrytumor celltumor cellHai Hu[@CIT0026]2016China88not reported56/32I-IInot reportedimmunohistochemistrytumor celltumor stromatumor cell and stromatumor celltumor stromatumor cell and stromaAngela Diana[@CIT0025]2016Germany1416536/34not reportedmean 20 (2--69)immunohistochemistrytumor cellJack Hutcheson[@CIT0021]2016USA22365 (27-89)121/102not reportednot reportedimmunohistochemistrytumor celltumor stromatumor cell and stromaQiaofei Liu[@CIT0020]2016China95not reported62/33not reported(36-87)immunohistochemistrytumor cellWQ Wang[@CIT0023]2016China284not reportednot reportednot reportednot reportedimmunohistochemistry and polymerase chain reactiontumor cellErik S Knudsen[@CIT0011]2017USA109not reportednot reportednot reported18.67immunohistochemistrytumor cell and stroma[^2] AuthorCut-off valueMarkerPositive/negativeHazard ratiolow limit of 95% confidence intervalupper limit of 95% confidence intervalSurvival analysesDilutionAntibody (clone)Newcastle-Ottawa scale soreHiroshi Kurahara[@CIT0010]≥40/mm² positively stained macrophages (x400)CD6851/2510.511.96overall survival1：100Monoclonal, DAKO, Glostrup, Denmark7≥40/mm² positively stained macrophages (x400)CD16334/422.151.323.5overall survival1：50Monoclonal, Novocastra, Newcastle, UKKiyoshi Yoshikawa[@CIT0022]\>3.39% of infiltrating macrophagesCD20453/542.7811.744.445overall survival1:400Kumamoto,Japan7\>3.39% of infiltrating macrophagesCD20453/541.8641.1642.986overall survival1:400Kumamoto, JapanY Ino[@CIT0009]not reportedCD163106/1062.031.462.84overall survivalnot reportedLeica Microsystems, UK7not reportedCD68106/1062.331.683.22overall survivalnot reportedMonoclonal, DAKO, Glostrup, Denmarknot reportedCD204106/1061.381.011.89overall survivalnot reportedTrans Genic，Kumamoto, JapanYa-Chin Hou[@CIT0017]MeanCD20439/572.3371.0984.976overall survival1：500Abcam, Cambridge, United Kingdom7MeanCD20439/571.81.0063.22overall surviall1：500Abcam, Cambridge, United KingdomMotokazu Sugimoto[@CIT0024]≥Median valueCD20485/852.1671.5223.086overall survival1：400Trans Genic，Kumamoto, Japan6≥Median valueCD20485/851.8311.2972.583overall survial1：400Trans Genic，Kumamoto, JapanS.J. Chen[@CIT0019]\>21.0 cells/field(400 x)CD16334/361.861.113.12overall survival1：500Abcam, Cambridge, United Kingdom8\>45.0 cells/field(400 x)CD16337/332.311.274.21overall survival1：500Abcam, Cambridge, United KingdomKazuki Takakura[@CIT0018]≥Median valueCD16314/144.7841.8314.133overall survival1：500Abcam, Cambridge, United Kingdom8≥Median valueCD16314/143.6521.4879.845disease- free survival1：500Abcam, Cambridge, United KingdomHai Hu[@CIT0026]\>40 macrophages per mm²CD6829/591.380.82.38overall survivalnot reportednot reported6\>40 macrophages per mm²CD6843/451.440.852.42overall survivalnot reportednot reported\>40 macrophages per mm²CD6846/421.250.742.11overall survivalnot reportednot reported\>40 macrophages per mm²CD16320/681.580.882.86overall survivalnot reportednot reported\>40 macrophages per mm²CD16334/546.351.428.87overall survivalnot reportednot reported\>40 macrophages per mm²CD16332/560.270.061.23overall survivalnot reportednot reportedAngela Diana[@CIT0025]≥Median valueCD6865/760.968990.80841.16279overall survivalnot reportedMonoclonal, DAKO, Glostrup, Denmark7Jack Hutcheson[@CIT0021]≥Median valueCD16368/762.0581.2293.448overall survival1:100Clone 10D6, Leica8≥Median valueCD16388/881.4810.9542.298overall survival1:100Clone 10D6, Leica≥Median valueCD16344/441.8510.9293.688overall survival1:100Clone 10D6, LeicaQiaofei Liu[@CIT0020]≥Median valueCD16348/472.11.243.54overall survival1:100Abcam, Cambridge, United Kingdom7WQ Wang[@CIT0023]≥Median valueCD20629/500.24330.1230.478relapse- free survival1:100Zymed Laboratories, San Francisco, California, USA7Erik S. Knudsen[@CIT0011]\>40 macrophages per mm²CD68377/7651.741.492.02overall survivalnot reportednot reported8\>30 macrophages per mm²CD163356/7992.642.243.11overall survivalnot reportedCell Marque

Detection of tumor-associated macrophages {#S0003-S2002}
-----------------------------------------

Examination methods were mainly IHC, one of which combined with PCR. Multiple markers were used to estimate tumor-associated macrophages. CD68 was used for identification of TAMs in 5 of the 13 included studies, including 4 studies in combination with CD163,[@CIT0009],[@CIT0011],[@CIT0022],[@CIT0026] 1 study in combination with CD204.[@CIT0010] Four studies only selected CD163 as a biomarker[@CIT0018]--[@CIT0021] and 3 studies only selected CD204[@CIT0017],[@CIT0022],[@CIT0024] as the biomarker. Only one study only selected CD206 as a biomarker.[@CIT0023] We also can see the details of multiple markers in [Table 1](#T0001){ref-type="table"}. Stained sections were scanned at a magnification of X40 and authors marked the margin of the tumor on each slide. The center of lesion was defined as the intersection of the major and minor axes and four fields including the center at a magnification of X100. Peripheral site was defined as fields that included cancer cells and adjacent non-cancerous cells at a magnification of X100.[@CIT0022]

The association of TAMs with clinicopathological characteristics {#S0003-S2003}
----------------------------------------------------------------

The effect of elevated TAMs infiltration with the clinicopathological parameters in pancreatic cancer patients was further evaluated in our meta-analysis. Four of the 13 included studies have presented relevant data of the association between clinicopathological parameters and CD68+ TAMs.[@CIT0010],[@CIT0017],[@CIT0025],[@CIT0026] Three of the 13 included studies have presented relevant data of the association between clinicopathological parameters and CD204+ TAMs. Two of the 13 included studies have presented relevant data of the association between clinicopathological parameters and CD163+ TAMs. Moreover, there were three studies investigating the connection between M2 TAMs and clinicopathological parameters. It is a pity that there was not enough data for CD206+ TAMs. Pooled analysis showed no significant correlation between elevated CD68+ TAMs infiltration and LN metastasis (yes vs no) (OR =1.45, 95% CI =0.89--2.39, fixed effects model, *P*=0.136), tumor stage (T1/T2 vs T3/T4) (OR =0.60, 95% CI =0.36--1.02, fixed effects model, *P*=0.061), histological grade (III vs І, II) (OR =0.75, 95% CI =0.39--1.45, fixed effects model, *P*=0.394), sex (male vs female) (OR =0.69, 95% CI =0.43--1.10, fixed effects model, *P*=0.120), or tumor location (head/neck vs other) (OR =1.12, 95% CI =0.47--2.68, fixed effects model, *P*=0.730). Pooled analysis showed no significant correlation between elevated CD163+ TAMs infiltration and LN metastasis (yes vs no) (OR =2.69, 95% CI =0.52--14.03, random effects model, *P*=0.241), tumor stage (T1/T2 vs T3/T4) (OR =0.25, 95% CI =0.03--2.27, fixed effects model, *P*=0.219), histological grade (III vs І, II) (OR =3.00, 95% CI =0.51--17.50, fixed effects model, *P*=0.222), sex (male vs female) (OR =1.09, 95% CI =0.56--2.12, fixed effects model, *P*=0.802), or tumor location (head/neck vs other) (OR =0.51, 95% CI =0.21--1.27, fixed effects model, *P*=0.151). Pooled analysis showed no significant correlation between elevated CD204+ TAMs infiltration and LN metastasis (yes vs no) (OR =1.915, 95% CI =0.26--13.94, random effects model, *P*=0.525), tumor stage (T1/T2 vs T3/T4) (OR =0.72, 95% CI =0.27--1.95, fixed effects model, *P*=0.518), histological grade (III vs І, II) (OR =1.33, 95% CI =0.31--5.67, random effects model, *P*=0.801), sex (male vs female) (OR =1.10, 95% CI =0.58--2.11, fixed effects model, *P*=0.771), or tumor location (head/neck vs other) (OR =1.17, 95% CI =0.48--2.87, fixed effects model, *P*=0.724) as well. The same result also happened when we investigated M2-TAMs. The details about the association of TAMs with clinicopathological characteristics are shown in [Tables 2](#T0002){ref-type="table"}--[5](#T0005){ref-type="table"}.Table 2Meta-analysis of high CD68+ TAMs infiltration and clinicopathological features of pancreatic cancer patientsPatient characteristicsOdds ratio (95% confidence interval)Heterogeneity(CD68 High vs Low)References of studiesNumber of patientsFixedRandomI^2^*P*-valueLymph node metastasis\
(yes vs no)[@CIT0010], [@CIT0026], [@CIT0025]3051.45 (0.89--2.39)1.49 (0.81--2.73)32.00%0.23Tumor stage\
(T1/T2 vs T3/T4)[@CIT0010], [@CIT0017], [@CIT0026], [@CIT0025]4010.60 (0.36--1.02)0.61 (0.36--1.03)00.67Histological grade (III vs І, II)[@CIT0010], [@CIT0026]2160.75 (0.39--1.45)0.75 (0.39--1.45)00.534Sex (male vs female)[@CIT0010], [@CIT0026], [@CIT0025]3050.69 (0.43--1.10)0.69 (0.43--1.10)00.767Tumor location (head/neck vs other)[@CIT0026], [@CIT0025]2291.12 (0.47--2.68)1.11 (0.47--2.66)46.20%0.173 Table 3Meta-analysis of high M2-TAMs infiltration and clinicopathological features of pancreatic cancer patientsPatient characteristicsOdds ratio (95% confidence interval)Heterogeneity(Type 2 macrophages High vs Low)References of studiesNumber of patientsFixedRandomI^2^*P*-valueLymph node metastasis (yes vs no)[@CIT0010], [@CIT0017], [@CIT0026]2601.90 (1.21--2.98)2.22 (0.76--6.46)79.20%0.002Tumor stage (T1/T2 vs T3/T4)[@CIT0010], [@CIT0026]1640.58 (0.24--1.39)0.63 (0.24--1.61)00.392Histological grade (III vs І, II)[@CIT0010], [@CIT0017]1721.37 (0.63--2.98)1.57 (0.54--4.55)36.00%0.21Sex (male vs female)[@CIT0010], [@CIT0017], [@CIT0026]2601.09 (0.69--1.74)1.09 (0.69--1.74)00.888Tumor location (head/neck vs other)[@CIT0010], [@CIT0017]1840.79 (0.42--1.48)0.78 (0.35--1.75)38.10%0.204 Table 4Meta-analysis of high CD163+ TAMs infiltration and clinicopathological features of pancreatic cancer patientsPatient characteristicsOdds ratio (95% confidence interval)Heterogeneity(CD163 High vs Low)References of studiesNumber of patientsFixedRandomI^2^*P*-valueLymph node metastasis (yes vs no)[@CIT0010], [@CIT0026]1642.28 (1.14--4.56)2.69 (0.52--14.03)81.40%0.021Tumor stage (T1/T2 vs T3/T4)[@CIT0010]760.25 (0.03--2.27)0.25 (0.03--2.27)..Histological grade (III vs І, II)[@CIT0010]763.00 (0.51--17.50)3.00 (0.51--17.50)..Sex (male vs female)[@CIT0010], [@CIT0026]1641.09 (0.56--2.12)1.09 (0.56--2.12)00.602Tumor location (head/neck vs other)[@CIT0010]880.51 (0.21--1.27)0.51 (0.21--1.27).. Table 5Meta-analysis of high CD204+ TAMs infiltration and clinicopathological features of pancreatic cancer patientsPatient characteristicsOdds ratio (95% confidence interval)Heterogeneity(CD204 High vs Low)References of studiesNumber of patientsFixedRandomI^2^*P*-valueLymph node metastasis (yes vs no)[@CIT0010], [@CIT0017]1721.45 (0.75--2.81)1.91 (0.26--13.94)87.90%0.004Tumor stage (T1/T2 vs T3/T4)[@CIT0010], [@CIT0026]1640.72 (0.27--1.95)0.76 (0.25--2.26)00.756Histological grade (III vs І, II)[@CIT0010], [@CIT0017]1721.12 (0.47--2.68)1.33 (0.31--5.67)52.90%0.145Sex (male vs female)[@CIT0010], [@CIT0017]1721.10 (0.58--2.11)1.10 (0.58--2.11)00.545Tumor location (head/neck vs other)[@CIT0017]961.17 (0.48--2.87)1.17 (0.48--2.87)..

Association of M2-TAMs with the survival of pancreatic cancer {#S0003-S2004}
-------------------------------------------------------------

As we can see in [Figure 2A](#F0002){ref-type="fig"}, the pooled results of eleven studies showed that patients with high M2-TAMs infiltration had significantly decreased OS compared to those with low/negative M2-TAMs infiltration (HR =1.95, 95% CI =1.63--2.33, random effects model, I^2^=59.2%, *P*=0.000). Furthermore, a subgroup analysis according to the M2-TAMs in different sample distribution also showed that the high M2-TAMs infiltration indicated a significant correlation with worse OS in pancreatic cancer patients whose biomarkers were detected in tumor cell and stroma (HR =1.89, 95% CI =1.39--2.56, *P*=0.000) (Figure S1A, distribution = tumor cell and stroma), tumor stroma (HR =2.19, 95% CI =1.65--2.90, *P*=0.000) (Figure S1A, distribution = stroma), and tumor cell (HR =1.80, 95% CI =1.29--2.50, *P*=0.001) (Figure S1A, distribution = tumor cell). We also conducted a subgroup analysis among the pancreatic cancer patients, according to the country. The pooled HRs demonstrated M2-TAMs correlated with worse OS in pancreatic cancer patients in the non-Asian country (HR =2.08, 95% CI =1.52--2.83, *P*=0.000) (Figure S1B). And there was a significant connection between CD163+ TAMs and worse OS in pancreatic cancer patients in the Asian country (HR =1.91, 95% CI =1.55--2.36, *P*=0.000) (Figure S1B). Based on the number of patients in studies, a subgroup analysis, in which studies were divided into two groups, was conducted. The pooled data indicated that M2-TAMs correlated with worse OS in pancreatic cancer patients in the studies whose patient number were below 100 (HR =2.05, 95% CI =1.58--2.67, *P*=0.000) ([Figure S1C](#SF0001)). There was a significant connection between M2-TAMs and worse OS in pancreatic cancer patients in the studies whose patient number were above or equal to 100 (HR =1.88, 95% CI =1.47--2.40, *P*=0.000) (Figure S1C). In order to seek the source of heterogeneity further, we conducted a subgroup analysis as well, according to the quality of studies. As shown in Figure S1D, the pooled HR showed that M2-TAMs correlated with worse OS in pancreatic cancer patients in the studies whose score were 7 (HR =1.83, 95% CI =1.41--2.36, *P*=0.000) and in pancreatic cancer patients in the studies whose score were 8 (HR =2.18, 95% CI =1.75--2.73, *P*=0.000). In contrast, there was a significant connection between M2-TAMs and worse OS in pancreatic cancer patients in the studies whose score were 6 (HR =1.69, 95% CI =0.83--3.44, *P*=0.151) ([Figure S1D](#SF0001)).Figure 2Forest plot of hazard ratio (HR) for the association between OS and M2-TAMs: all studies about M2-TAMs (**A**); all studies about M2-TAMs except the last included study (**B**).

As for the prognostic value of M2-TAMs on DFS, the pooled results of three studies[@CIT0017],[@CIT0018],[@CIT0024] that elevated M2-TAMs density was significantly associated with the DFS (HR =1.83, 95% CI =1.43--2.36, fixed effects model, I^2^=0.0%, *P*=0.000) (details in [Figure 3](#F0003){ref-type="fig"}).Figure 3Forest plot of hazard ratio (HR) for the association between DFS and M2-TAMs.

The association between CD68+TAMs and prognostic outcomes {#S0003-S2005}
---------------------------------------------------------

To further investigate the prognostic role of CD68+ TAMs on OS, the pooled HRs demonstrated CD68+ TAMs correlated with worse OS in pancreatic cancer patients (HR =1.41, 95% CI =1.05--1.99, random effects model, I^2^=82.5%, *P*=0.021) ([Figure 4](#F0004){ref-type="fig"}). We conducted a subgroup analysis according to the CD68+ TAMs in different sample distribution. Results demonstrated that there was no significant association between CD68+ TAMs and OS in pancreatic cancer patients whose CD68+ were detected in tumor cell (HR =1.05, 95% CI =0.79--1.40, *P*=0.743) ([Figure S2A](#SF0002)). The same result was also found when talking about the association between CD68+ TAMs and OS in pancreatic cancer patients whose CD68+ were identified in tumor stroma (HR =1.44, 95% CI =0.85--2.43, *P*=0.172) ([Figure S2A](#SF0002)). In contrast, the pooled HRs demonstrated CD68+ TAMs correlated with worse OS in pancreatic cancer patients whose CD68+ were detected in tumor cell and stroma (HR =1.66, 95% CI =1.25--2.20, *P*=0.000) ([Figure S2A](#SF0002))Figure 4Forest plot of hazard ratio (HR) for the association between OS and CD68+ TAMs: all studies about CD68+ TAMs (**A**); all studies about CD68+ TAMs except the ninth included study and the last included study (**B**).

Prognostic significance of CD163+TAMs in pancreatic cancer patients {#S0003-S2006}
-------------------------------------------------------------------

As for the prognostic value of CD163+ TAMs on OS, the pooled results of eight studies that elevated CD163+ density was significantly associated with the worse OS (HR =2.26, 95% CI =2.01--2.53, fixed effects model, *P*=0.000) and presented a significant degree of heterogeneity (I^2^=43.9%, *P*=0.045) (details in [Figure 5](#F0005){ref-type="fig"}). In view of the existence of substantial heterogeneity, based on the CD163+ TAMs in different sample distribution, we conducted a subgroup analysis. The pooled HRs demonstrated CD163+ TAMs correlated with worse OS in pancreatic cancer patients, regardless of the CD163+ identified in tumor cell (HR =2.02, 95% CI =1.56--2.62, *P*=0.000) or in tumor stroma (HR =1.85, 95% CI =1.31--2.61, *P*=0.000) ([Figure S2B](#SF0002)). As for the OS in pancreatic cancer patients in reference to tumor cell and stroma, there was also significant connection with high CD163+ TAMs infiltration (HR =2.40, 95% CI =2.09--2.76, *P*=0.000) ([Figure S2B](#SF0002)).Figure 5Forest plot of hazard ratio (HR) for the association between OS and CD163+ TAMs: all studies about CD163+ TAMs (**A**); all studies about CD163+ TAMs except the last included study (**B**).

Impact of CD204+TAMs on survival outcomes {#S0003-S2007}
-----------------------------------------

To further elucidate the role of CD204+ TAMs infiltration on survival outcomes, we investigated the correlation between CD204+ TAMs density and OS of pancreatic cancer patients. As shown in [Figure 6](#F0006){ref-type="fig"}, the pooled results of eight studies that elevated CD204+ density was significantly associated with the worse OS (HR =1.77, 95% CI =1.24--2.52, random effects model, *P*=0.002) and presented a significant degree of heterogeneity (I^2^=70.4%, *P*=0.009). A subgroup analysis was conducted by us according to the CD204+ TAMs in different sample distribution to seek for the source of substantial heterogeneity. The pooled HRs demonstrated CD204+ TAMs did not correlate with worse OS in pancreatic cancer patients whose CD204+ were detected tumor cell (HR =1.04, 95% CI =0.67--1.59, *P*=0.876) ([Figure S2C](#SF0002)). As for the OS in pancreatic cancer patients whose CD204+ were identified in tumor cell and stroma, there was significant connection with high CD163+ TAMs infiltration (HR =1.60, 95% CI =1.01--2.54, *P*=0.047) ([Figure S2C](#SF0002)). As for the OS in pancreatic cancer patients whose CD204+ were identified in tumor stroma, there was also significant connection with high CD204+ TAMs infiltration (HR =2.37, 95% CI =1.79--3.15, *P*=0.000) ([Figure S2C](#SF0002)).Figure 6Forest plot of hazard ratio (HR) for the association between OS and CD204+ TAMs.

As for the prognostic value of CD204+ TAMs on DFS, the pooled results of three studies[@CIT0017],[@CIT0018],[@CIT0024] that elevated CD204+ TAMs density was significantly associated with the DFS (HR =1.83, 95% CI =1.43--2.36, fixed effects model, I^2^=0.00%, *P*=0.000) (details in [Figure 7](#F0007){ref-type="fig"}).Figure 7Forest plot of hazard ratio (HR) for the association between DFS and CD204+ TAMs.

Impact of CD206+TAMs on survival outcomes {#S0003-S2008}
-----------------------------------------

There was only one study which involved the connection between CD206+ TAMs infiltration and RFS of pancreatic cancer patients. As shown in [Table 1](#T0001){ref-type="table"}, the data presented that CD206+ TAMs correlated with better RFS in pancreatic cancer patients (HR =0.24, 95% CI =0.12--0.48).[@CIT0023]

Sensitivity analysis {#S0003-S2009}
--------------------

We conducted a sensitivity analysis by removing each study to evaluate the effect of individual datasets on the pooled HRs.

In the procedure of investigating the connection between M2-TAMs and OS of pancreatic cancer, we found similar HRs and 95% CIs except for the situation when we omitted the last included study (details in Figure S3A). When we omitted the last included study,[@CIT0011] the heterogeneity decreased from 59.2% to 45.4%. The pooled data changed simultaneously (HR =1.83, 95% CI =1.63--2.07, fixed effects model, *P*=0.000) (details in [Figure 2B](#F0002){ref-type="fig"}). As for the connection between M2-TAMs and DFS of pancreatic cancer, as shown in Figure S3B, we found similar HRs and 95% CIs, indicating that the result of RFS was relatively stable.

In the procedure of investigating the connection between CD68+ TAMs and OS of pancreatic cancer, we found similar HRs and 95% CIs except for the situation when we omitted the ninth included study and the last included study[@CIT0011],[@CIT0025] (details in [Figure S3C](#SF0003)). When we omitted the ninth included study and the last included study,[@CIT0011],[@CIT0025] the heterogeneity decreased from 82.5% to 51.2%. As we can see in [Figure 4B](#F0004){ref-type="fig"}, the pooled data also changed. (HR =1.51, 95% CI =1.10--2.08, random effects model, *P*=0.011).

In the procedure of investigating the connection between CD163+ TAMs and OS of pancreatic cancer, we found similar HRs and 95% CIs except for the situation when we omitted the last included study (details in Figure S3D). Then, we omitted the last included study,[@CIT0011] the heterogeneity decreased from 43.9% to 24.5%. At the same time, the pooled HR and 95% CI changed (HR=1.95, 95% CI=1.67--2.28, fixed effects model, *P*=0.000) (details in [Figure 5B](#F0005){ref-type="fig"}).

In the procedure of investigating the connection between CD204+ TAMs and OS of pancreatic cancer, the results shown in Figure S3E indicated that the pooled HRs for OS was not substantially changed. As for the connection between CD204+ TAMs and DFS of pancreatic cancer, as shown in Figure S3F, our findings of the pooled HRs were also robust.

Publication bias {#S0003-S2010}
----------------

Both Begg's test and Egger's test were performed to estimate the publication bias of the included studies. As shown in [Figure S4](#SF0004), Begg's test showed that there was no statistical evidence of publication bias in our meta-analysis. Similarly, Egger's linear regression did not reveal obvious publication bias (detail in [Figure S5](#SF0005)).Figure S4Begg's test for the assessment of publication bias in the present study, (**A**) Begg's test of M2-TAMS on OS; (**B**) Begg's test of M2-TAMS on DFS; (**C**) Begg's test of CD68+ TAMS on OS; (**D**) Begg's of CD163+ TAMS on OS; (**E**) Begg's test of CD204+ TAMS on OS﻿ (**F**) Begg's test of CD204+ TAMS on DFS.Figure S5Egger's test for the assessment of publication bias in the present study, (**A**) Egger's test of M2-TAMS on OS; (**B**) Egger's test of M2-TAMS on DFS; (**C**) Egger's test of CD68+ TAMS on OS; (**D**) Egger's test of CD163+ TAMS on OS; (**E**) Egger's test of CD204+ TAMS on OS; (**F**) Egger's test of CD204+ TAMS on DFS.

Discussion {#S0004}
==========

As a kind of malignant tumor, pancreatic cancer is the fourth leading cause of cancer mortality in the world. It is so difficult to diagnose and treat patients with a pancreatic tumor that the five-year survival rate is nearly 5%. The success rate of the radical operation has been improved much than ever, but the prognosis of patients who suffer pancreatic cancer has not changed accordingly. Consequently, there is an urgent need to seek for novel therapeutic strategies. Accumulated studies have demonstrated that tumor microenvironment plays particular functional roles in tumor progression, including cancer initiation and promotion, immune suppression, metastasis, establishing a premalignant niche.[@CIT0027],[@CIT0028] It is confirmed that tumor microenvironment consists of tumor cells, immune cells, cytokines, and extracellular matrix.[@CIT0029] Among them, especially, TAMs occupy a prominent position that orchestrates various factors in the tumor microenvironment,[@CIT0030],[@CIT0031] connecting with tumor cells. Therefore, targeting TAMs can be regarded as a novel strategy for the treatment of pancreatic cancers. However, the connection between TAMs and outcome of pancreatic cancer remains contradictory. Our meta-analysis of 13 publications including 1699 patients revealed elevated M2-TAMs infiltration predicted worse OS and DFS. What's more, different from the results in the first, the eighth, and the ninth included studies,[@CIT0010],[@CIT0025],[@CIT0026] high-density CD68+ TAMs infiltration connected with worse OS. What's more, our meta-analysis revealed that there was no significance between elevated clinicopathological characteristics and high-density TAMs, neither M2-TAMs nor CD68+ TAMs.

Recently, different subtypes and distribution of TAMs caught attention of many researchers who aim to investigate the roles of TAMs in prognostic prediction comprehensively. In general, TAMs have two polarization subtypes: M1 and M2. M1 are involved in helper T cell (Th) 1 response to infection. On the contrary, M2-TAMs contribute to promoting tumor progression.[@CIT0027] In most cases, M1 macrophages generally express markers CD80, CD86, human leukocyte antigen (HLA)-DR and inducible nitric oxide synthase (iNOS), while M2 macrophages generally identified by the markers such CD163, CD204, CD206, and Arginase 1.[@CIT0032],[@CIT0033] However, CD68, as a common marker, identifies both M1 and M2 TAMs and cannot reflect the TAMs polarization subtypes. So, TAMs labeled by CD68 are also called generalized TAMs. Several studies indicated elevated CD68+ TAMs infiltration did not connect with worse OS.[@CIT0010],[@CIT0025],[@CIT0026] The reason might be because of the neutralization of the M1 and M2 prognostic effects. In our meta-analysis, CD68 was used for identification of TAMs in 5 of the 13 included studies and the pooled HRs demonstrated CD68+ TAMs correlated with worse OS in pancreatic cancer patients. At the same time, the heterogeneity is very large, and we need to pay attention when interpreting it. Thus, further studies with larger sample size and more details are still needed to validate our conclusion about CD68+ TAMs. M2-TAMs can be a predictive factor of prognosis in pancreatic cancer patients. CD163, CD204 or CD206 were used for identification of TAMs in all included studies. Although, in our meta-analysis, high CD206+ TAMs density associated with better RFS. However, this result was merely abstracted from one study.[@CIT0023] While there was a significant association between M2-TAMs and survival rates of pancreatic cancer patients. The reason that high-density M2-TAMs associated with poor survival rate (OS and DFS) is the roles of M2-TAMs in tumor progression, including cancer initiation and promotion, immune suppression, metastasis, establishing a premalignant niche. In the aspect of cancer initiation and promotion, M2-TAMs connect inflammation and cancer. TAMs that secreted cytokines IL-23 and IL-17 drive "tumor-elicited inflammation" and promote colorectal cancer progression.[@CIT0034] Recent data indicates the increased IL-6 derived from TAMs had an amplifying effect on the inflammation response and further promoted the occurrence and development of hepatocellular carcinoma.[@CIT0035] In the aspect of immune suppression, TAMs involved in inhibiting cytotoxic T lymphocyte (CTL) responses in tumor microenvironments. Evidences indicated the expression of costimulatory molecule PD-L1 in monocytes could be induced by IL-10 derived from TAMs in hepatocellular carcinoma, which can inhibit CTL responses.[@CIT0036] In the aspect of cancer initiation and promotion, TAMs promote solid tumor development by providing factors that enhance metastasis and the establishment of a premalignant niche of malignant cells. The epithelial--mesenchymal transition (EMT), whose initiation and progression are affected by TAM-derived factors such as transforming growing factor-β~1~ (TGF-β~1~), plays a fundamental role in tumor progression and metastasis.[@CIT0037] Tumor necrosis factor-α (TNF-α), vascular endothelial growth factor (VEGF) and transforming growing factor-β (TGF-β) derived from TAMs in cancer tissues, are believed that they can induce macrophages to produce S100A8 and serum amyloid A3 after they reach destination organs. Both of S100A8 and serum amyloid A3 can recruit macrophages and tumor cells to destination organs and promote the formation of metastatic foci.[@CIT0037] Taking all into account, targeting TAMs, which are thought to more closely resemble M2-polarized macrophages, may provide us with a novel therapeutic strategy.

To the best of our knowledge, this is the first meaningful meta-analysis shedding light on the prognostic value of TAMs in pancreatic cancer. Our study also tells us some important messages. First, although one study suggested high CD206+ TAMs density associated with better relapse-free survival (RFS), it was convinced that the high-density M2-TAMs was associated with poor results in pancreatic cancer patients. Therefore, we can assume that M2-TAMs may provide us with a potential therapeutic target. Elevated density CD68+ TAMs could also predict the prognosis of pancreatic cancer patients. Due to the significant heterogeneity, the prognostic role of CD68+ TAMs remains controversial. Second, it concludes that there was a significant connection between elevated M2-TAMs density and OS in pancreatic cancer patients, regardless of the CD163+ and CD204+ identified in whole sample area (or not specified), tumor stroma or tumor cell. Besides, M2-TAMs correlated with worse OS in pancreatic cancer patients both in the non-Asian country and the Asian country. Finally, based on the function of TAMs, overall survival of all patients with elevated density TAMs seem to be worse clinicopathological characteristics than those with low-density TAMs, albeit not significantly. In our meta-analysis, the pooled analysis showed that elevated TAMs infiltration had nothing to do with LN metastasis, tumor stage, histological grade, sex, or tumor location. Our study only showed four clinicopathologic factors. There are still other clinicopathologic factors, such as tumor size, venous invasion, margin status, and so on. Kurahara reported the density of CD204+ TAMs in tumors with venous invasion were significantly higher than those without this factor.[@CIT0010] Yoshikawa also reported there was a significant connection between cases with portal vein invasion and high central CD204 expression.[@CIT0022] As a result, we can guess TAMs have an impact on the prognosis by other ways, like venous invasion. Moreover, only 4 of the 13 included studies have presented relevant data of the association between clinicopathological parameters and TAMs. Therefore, further studies with larger sample size and more detailed information are still needed to validate our conclusion.

However, there are also some limitations existing in our study. First, there was significant heterogeneity among the analysis of M2-TAMs on OS, CD68+ TAMs on OS, and CD204+ TAMs on OS. But it is a common phenomenon that heterogeneity among the studies existed when we conduct a meta-analysis of observational studies. According to the results of sensitivity analysis, the study from Knudsen and his team is the source of statistical heterogeneity in the meta-analysis. In our meta-analysis, the differences in the quality of studies, the country, the number of patients, sample size, cut-off value, tissue distribution and the antibodies and dilution, which was applied to detect the TAMs density, might be the sources of heterogeneity. After we conducted all subgroup analysis, we found that, among the above factors, tissue distribution might be the most critical factor. The reason might be that there was no explicit boundary between three kinds of tissue distribution. This may lead to bias into the evaluation of tumor-associated macrophage infiltration when different searchers investigated them. Moreover, the included studies selected different kinds of antibodies or dilution when the authors detected the density and distribution of TAMs. Third, it has not reached consensus on cut-off value, which was used to identify the density of the TAMs. Besides, studies included in our meta-analysis were limited in the English language. Considering these limitations, large-scale prospective studies with high quality are still needed to validate the conclusion from our result.

In summary, our meta-analysis demonstrated that the density of TAMs has an impact on the survival rate of patients with pancreatic cancer. Our study demonstrated that the elevated density of M2-TAMs predicted poor survival in pancreatic cancer patients, specially CD163+ TAMs and CD204+ TAMs. Elevated density CD68+ TAMs could also predict the prognosis of pancreatic cancer patients. Moreover, further studies and multiple centers clinical trials are required to confirm the result of our study.
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Figure S1Forest plot of hazard ratio (HR) for the subgroup analyses of M2-TAMS: the tissue distribution of paper (**A**), the country of paper (**B**), the number of patients of the paper source (**C**), the quality of the paper (**D**). Figure S2Forest plot of hazard ratio (HR) for the subgroup analyses of the tissue distribution of paper: CD68+ TAMS on OS (**A**); CD163+ TAMS on OS (**B**); CD204+ TAMS on OS (**C**). Figure S3Sensitivity analysis was performed in present studies. (**A**) M2-TAMS on OS; (**B**) M2-TAMS on DFS; (**C**) CD68+ TAMS on OS; (**D**) CD163+ TAMS on OS; (E) CD204+ TAMS on OS; (F) CD204+ TAMS on DFS.

**Supplementary text 1**

The full electronic strategy of databases

The full electronic strategy for PubMed

The following search terms were variously combined: "pancreatic cancer", "pancreatic carcinoma", "pancreatic duct adenocarcinoma", "pancreatic ductal adenocarcinoma", "macrophage", "tumor-associated-macrophages", "tumor-infiltrating-macrophages", "tumor infiltrating macrophages" and "TAMs". We search the studies which were published before November 2018.

Search formula of PubMed:(\#pancreatic cancer OR \#pancreatic carcinoma OR \#pancreatic duct adenocarcinoma OR \#pancreatic ductal carcinoma) AND (\#macrophage OR \#tumor-associated-macrophages OR \#tumor associated macrophages OR \#TAMs OR \#tumor infiltrating macrophages OR \#tumor-infiltrating-macrophages)

[^1]: These authors contributed equally to this work

[^2]: **Abbreviations:** IHC, immunohistochemistry; PCR, polymerase chain reaction; HR, hazard ratio; LCI, low limit of 95% confidence interval; UCI, upper limit of 95% confidence interval; OS, overall survival; NOS, Newcastle-Ottawa Scale; DFS, disease-free survival; RFS, relapse-free survival.
